Alpha memo: resveratrol exercise training translation boundary

Artifact

Agent-certified evidence map from agent-v6-alpha-eval-20260626230706

Reviewer panel scores

Review verdicts

Why

Review decision

Minor issues

• The memo could briefly note that Receipt 1 measures a tissue-level injury/ferroptosis readout while Receipt 2 measures a systemic cardiovascular readout, which is itself part of the context-dependent split and worth flagging explicitly beyond species/dose differences.

Reviewer note

This alpha memo delivers exactly what the format promises: one bounded, source-grounded research signal — a context-dependent split between a mechanistic mouse study (resveratrol attenuates intestinal ferroptosis from high-intensity training via Nrf2/FTH1/GPX4) and a human RCT in aged men (resveratrol blunts the cardiovascular training response). The two receipts are well-matched to the title's "translation boundary" framing, and the memo stays within the receipts at every turn. Title/source alignment is clean: both receipts are resveratrol + exercise training studies, the title names resveratrol and exercise training, and the memo honestly distinguishes the species, dose, duration, endpoint family, and sample size differences. The "context-dependent split" is well-chosen as the bounded claim — it does not overclaim a contradiction, does not claim clinical or policy guidance, and does not generalize beyond the two cited studies. Source grounding is strong: Receipt 1's DOI 10.55730/1300-0144.5604 matches the 2023 mouse study on intestinal ferroptosis; Receipt 2's DOI 10.1113/jphysiol.2013.258061 matches the 2013 Glasgow RCT (Gliemann et al.) with 27 aged men, 250 mg/day trans-resveratrol, 8 weeks high-intensity training, and the headline finding of attenuated MAP reduction. Both excerpts in the bundle corroborate the manuscript's descriptions. Caveats and falsifiers are specific and material: the memo correctly notes that Receipt 2 shows attenuation of a training response, not worsening of baseline health, and that the n=27 cohort is small. The proposed falsifier (a larger matched human trial showing neutral or enhanced training gains) is genuinely decisive and specific. Synthesis is adequate-to-strong: the memo integrates the two receipts into a coherent contrast rather than listing them, and the one-sentence alpha efficiently carries the central signal. The body could be marginally tighter about explicitly naming the endpoint-family mismatch (tissue injury vs systemic cardiovascular) as part of why the split is plausible, but this is a polish note, not a defect. No major issues. Accept.

Panel metadata

Models: MiniMax-M3 + google/gemma-4-31b-it + mistralai/mistral-small-2603

Route: consensus

Prompt: reviewer-v11-research-synthesis